AUTHORS
Lianxuan Liu, BS, Mingming Zhang, PhD2, Shan Fu3, Jingjing Feng4, Ruimin Hong5, Guoqing Wei6, Houli Zhao7, Alex H. Zhang, Dr.8, Yongxian HU, MD9, He Huang, MD, PhD10
AFFILIATIONS
1 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
3 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
4 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
5 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
6 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
7 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
8 Shanghai YaKe Biotechnology Ltd, Shanghai, China
9 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
10 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
ABSTRACT
Background
A combination of tyrosine kinase inhibitor and chimeric antigen receptor (CAR) T-cell therapy showed feasibility and great early efficacy in patients with newly-diagnosed Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), in a previous nonrandomized clinical trial, at a median follow-up of 23.9 months. Here, we reported the long-term safety and efficacy of this therapy.
Methods
For adults with newly diagnosed Ph-positive ALL enrolled in this study, dasatinib was administered with a two-week vindesine and glucocorticoid regimen as induction, followed by sequential infusions of CD19 and CD22 CAR T-cells and single-agent dasatinib maintenance. The primary endpoint was complete molecular response (CMR) rate after CD19 CAR T-cell therapy. This report focuses on the long-term follow-up and discusses them in the context of previously reported early outcomes.
Results
A total of 28 patients were enrolled, among whom 1 patient withdrew from the study after induction therapy, and 27 patients ultimately received sequential CAR-T cell infusion. With a median extended follow-up of 40.67 months, the sustained CMR rate reached 74% (20/27, 95%CI: 53.7%–88.9%), and 2 additional patients maintained long-term major molecular response (MMR). Disease relapse occurred in 5 patients at a median relapse time of 26.7 months (range: 5.2–34.2 months), including 3 relapse cases that emerged after discontinuation of TKI therapy. IKZF1 mutations were detected in 60% (3/5) of relapsed patients, and 3 patients died of progressive disease during follow-up. Neither median leukemia-free survival (LFS) nor overall survival (OS) was reached. The 3-year LFS and OS rates were 79.0% (95%CI: 62.3%–95.7%) and 92.6% (95%CI: 82.8%–100%), respectively. Previously reported short-term adverse events were predominantly hematological toxicities and low-grade cytokine release syndrome (all grade 1, occurring in 21 of 52 CAR-T treatment cycles). Notably, no late-onset or persistent long-term adverse events were observed in the extended follow-up period.
Conclusions
The combined regimen of dasatinib plus sequential CD19/CD22 CAR-T therapy yields durable molecular remission and favorable long-term survival outcomes in adult patients with newly diagnosed Ph-positive ALL after extended follow-up. Few relapses occurred at a late median time point, and no persistent or late toxicities were identified beyond initial short-term adverse reactions.
DISCLOSURES
Lianxuan Liu, BS: No relevant conflicts of interest to declare.